Sanofi (NASDAQ:SNY) Stock Rating Lowered by Wall Street Zen

Sanofi (NASDAQ:SNY) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday.

Other research analysts have also recently issued research reports about the stock. Citigroup restated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a report on Monday, April 20th. Weiss Ratings downgraded Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Finally, Morgan Stanley set a $49.00 price objective on Sanofi in a research note on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $49.50.

Sanofi Trading Up 0.0%

Sanofi stock opened at $43.48 on Friday. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68. The firm has a market capitalization of $105.41 billion, a price-to-earnings ratio of 22.76, a P/E/G ratio of 1.08 and a beta of 0.35. The firm has a 50 day moving average of $43.32 and a 200 day moving average of $45.03. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21.

Hedge Funds Weigh In On Sanofi

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Trust Co. of Vermont bought a new stake in shares of Sanofi in the 2nd quarter worth about $212,000. Fiduciary Financial Group LLC lifted its holdings in shares of Sanofi by 33.8% in the 2nd quarter. Fiduciary Financial Group LLC now owns 8,403 shares of the company’s stock valued at $358,000 after acquiring an additional 2,124 shares during the last quarter. Fulton Bank N.A. grew its position in Sanofi by 5.6% in the second quarter. Fulton Bank N.A. now owns 68,196 shares of the company’s stock worth $2,909,000 after acquiring an additional 3,623 shares in the last quarter. First Bank & Trust grew its position in Sanofi by 23.4% in the second quarter. First Bank & Trust now owns 83,933 shares of the company’s stock worth $3,581,000 after acquiring an additional 15,937 shares in the last quarter. Finally, Focus Financial Network Inc. increased its stake in Sanofi by 9.2% during the second quarter. Focus Financial Network Inc. now owns 5,302 shares of the company’s stock worth $226,000 after acquiring an additional 446 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.